Back

Long-term efficacy of vutrisiran in patients with variant transthyretin amyloid cardiomyopathy

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Heart failure redefined: hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy precision treatments Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Takuto Zaizen

Oita University Faculty of Medicine, Oita (Japan)

6 More presentations in this session

Presentation thumbnail
Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: Post hoc safety analysis from HELIOS-B
Doctor S. Schwarting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Building on the demonstrated functional benefit of tafamidis: association of TTR stabilisation with 6MWT outcomes in ATTR ACT
Associate Professor M. Crespo-Leiro (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Estimated glomerular filtration rate trajectories by transthyretin stabilisation status in ATTR-ACT
Doctor S. Perlini (Pavia, IT)
Abstract Slides
Presentation thumbnail
Comprehensive assessment of disease status in ATTRwt-CM: Integrating serum transthyretin levels with clinical parameters using stabilizer therapy
Assistant Professor K. Yoshie (Matsumoto, JP)
Abstract Slides
Presentation thumbnail
The importance of distinct cardiac MRI regional analyses to assess the effects of cliramitug on amyloid depletion from the Phase 1b study NI006-101
Doctor F. Aus Dem Siepen (Heidelberg, DE)
Abstract Slides

Access the full session

Session thumbnail
Heart failure redefined: hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy precision treatments

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Transthyretin-directed antisense oligonucleotide therapy effects on ATTRv myocardiopathy
20 May 2023
thumbnail
Congress Presentation
Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE
1 September 2024
thumbnail
Congress Presentation
Improved survival with around 5 years of continuous tafamidis treatment among patients with NYHA class III transthyretin amyloid cardiomyopathy
21 May 2022
thumbnail
Congress Presentation
Safety and clinical effects of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources